These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1060 related items for PubMed ID: 26121913

  • 41. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
    Song F, Yan P, Huang X, Wang C, Du H, Qu X, Wu R.
    BMC Cancer; 2022 Jan 06; 22(1):42. PubMed ID: 34991494
    [Abstract] [Full Text] [Related]

  • 42. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):325-39. PubMed ID: 20139221
    [Abstract] [Full Text] [Related]

  • 43. Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11.
    Cornall AM, Roberts JM, Garland SM, Hillman RJ, Grulich AE, Tabrizi SN.
    Int J Cancer; 2013 Nov 03; 133(9):2253-8. PubMed ID: 23616200
    [Abstract] [Full Text] [Related]

  • 44. Human papillomavirus type distribution in cervical intraepithelial neoplasia grade 2/3 and cervical cancer in Portugal: a CLEOPATRE II Study.
    Pista A, de Oliveira CF, Lopes C, Cunha MJ, CLEOPATRE Portugal Study Groupa.
    Int J Gynecol Cancer; 2013 Mar 03; 23(3):500-6. PubMed ID: 23392401
    [Abstract] [Full Text] [Related]

  • 45. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN).
    Srodon M, Stoler MH, Baber GB, Kurman RJ.
    Am J Surg Pathol; 2006 Dec 03; 30(12):1513-8. PubMed ID: 17122506
    [Abstract] [Full Text] [Related]

  • 46. Genotype distribution of human papillomavirus (HPV) in histological sections of cervical intraepithelial neoplasia and invasive cervical carcinoma in Madrid, Spain.
    García-Espinosa B, Moro-Rodríguez E, Alvarez-Fernández E.
    BMC Cancer; 2012 Nov 20; 12():533. PubMed ID: 23167826
    [Abstract] [Full Text] [Related]

  • 47. Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA): A Trial Protocol.
    Stankiewicz Karita HC, Hauge K, Magaret A, Mao C, Schouten J, Grieco V, Xi LF, Galloway DA, Madeleine MM, Wald A.
    JAMA Netw Open; 2019 Apr 05; 2(4):e190819. PubMed ID: 30977845
    [Abstract] [Full Text] [Related]

  • 48. Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions.
    Iwata T, Hasegawa T, Ochiai K, Takizawa K, Umezawa S, Kuramoto H, Ohmura M, Kubushiro K, Arai H, Sakamoto M, Motoyama T, Watanabe K, Aoki D.
    Reprod Sci; 2015 Dec 05; 22(12):1509-15. PubMed ID: 26092278
    [Abstract] [Full Text] [Related]

  • 49. Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine.
    Luxembourg A, Kjaer SK, Nygard M, Ellison MC, Group T, Marshall JB, Radley D, Saah A.
    Contemp Clin Trials; 2017 Jan 05; 52():54-61. PubMed ID: 27777126
    [Abstract] [Full Text] [Related]

  • 50. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.
    Mesher D, Cuschieri K, Hibbitts S, Jamison J, Sargent A, Pollock KG, Powell N, Wilson R, McCall F, Fiander A, Soldan K.
    J Clin Pathol; 2015 Feb 05; 68(2):135-40. PubMed ID: 25410654
    [Abstract] [Full Text] [Related]

  • 51. Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV.
    Tachezy R, Smahelova J, Salakova M, Arbyn M, Rob L, Skapa P, Jirasek T, Hamsikova E.
    PLoS One; 2011 Feb 05; 6(7):e21913. PubMed ID: 21765924
    [Abstract] [Full Text] [Related]

  • 52. Five-year relative survival for human papillomavirus-associated cancer sites.
    Razzaghi H, Saraiya M, Thompson TD, Henley SJ, Viens L, Wilson R.
    Cancer; 2018 Jan 01; 124(1):203-211. PubMed ID: 29105738
    [Abstract] [Full Text] [Related]

  • 53. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.
    Vaccine; 2013 Aug 20; 31(37):3922-7. PubMed ID: 23806241
    [Abstract] [Full Text] [Related]

  • 54. Prevalence and distribution of high-risk human papillomavirus genotypes in invasive carcinoma of the uterine cervix in Uruguay.
    Berois N, De Cremoux P, Mazal D, Sica A, Cedeira M, Caserta B, Barrios E, Osinaga E, Sastre-Garau X.
    Int J Gynecol Cancer; 2013 Mar 20; 23(3):527-32. PubMed ID: 23392403
    [Abstract] [Full Text] [Related]

  • 55. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
    Perez S, Iñarrea A, Pérez-Tanoira R, Gil M, López-Díez E, Valenzuela O, Porto M, Alberte-Lista L, Peteiro-Cancelo MA, Treinta A, Carballo R, Reboredo MC, Alvarez-Argüelles ME, Purriños MJ.
    Virol J; 2017 Nov 06; 14(1):214. PubMed ID: 29110680
    [Abstract] [Full Text] [Related]

  • 56. Investigating a cluster of vulvar cancer in young women: a cross-sectional study of genital human papillomavirus prevalence.
    Rumbold AR, Tan SE, Condon JR, Taylor-Thomson D, Nickels M, Tabrizi SN, Davy ML, O'Brien MM, Connors CM, Zardawi I, Stankovich J, Garland SM.
    BMC Infect Dis; 2012 Oct 05; 12():243. PubMed ID: 23040203
    [Abstract] [Full Text] [Related]

  • 57. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.
    Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Harjula K, Kuortti M, Natunen K, Palmroth J, Petäjä T, Pukkala E, Siitari-Mattila M, Struyf F, Nieminen P, Paavonen J, Dubin G, Dillner J.
    BMJ Open; 2017 Aug 18; 7(8):e015867. PubMed ID: 28821519
    [Abstract] [Full Text] [Related]

  • 58. Value of cytologic Papanicolaou smears and polymerase chain reaction screening for human papillomavirus DNA in detecting anal intraepithelial neoplasia: comparison with histology of a surgical sample.
    Etienney I, Vuong S, Si-Mohamed A, Fléjou JF, Atienza P, Bauer P, Cytological Diaconesses Group.
    Cancer; 2012 Dec 15; 118(24):6031-8. PubMed ID: 22674290
    [Abstract] [Full Text] [Related]

  • 59. Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa.
    Denny L, Adewole I, Anorlu R, Dreyer G, Moodley M, Smith T, Snyman L, Wiredu E, Molijn A, Quint W, Ramakrishnan G, Schmidt J.
    Int J Cancer; 2014 Mar 15; 134(6):1389-98. PubMed ID: 23929250
    [Abstract] [Full Text] [Related]

  • 60. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
    Monsonego J, Zerat L, Syrjänen K, Zerat JC, Smith JS, Halfon P.
    Vaccine; 2012 Jul 27; 30(35):5215-21. PubMed ID: 22713720
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 53.